Skip to content
MARKETS / NASDAQ / HIND
NASDAQ · PHARMACEUTICAL PREPARATIONS

Vyome Holdings, Inc. HIND

12 fiscal years on record · USD · FY2025 reported · SEC filings only
$319,714
▲ 24.4% YoY
$-10.3M
In brief

What this company does

The Company also has a Pre-Investigational New Drug application stage ophthalmic drops program, a potential orphan drug program, VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis. The Company also has commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (“MRT”) in India - a dandruff lotion and shampoo. The Company operates in two segments, biotechnology and pharmaceutical products. Our biotechnology segment comprises our operations around our VT-1953, VT-1908, and VB-1953 programs that are in development, and our pharmaceutical segment comprises our antifungal products. We were incorporated as a Delaware company in 2017.

Written from the business description in Vyome Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 18 March 2026. Every sentence was checked against that document before publication.

Growth
USD 319,714.00
Revenue, FY2025 · full 12-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.3 · Net income -10.3
5.0M10.0M-25.0M-50.0M2014201620182020202220242025
Compound annual growth
−69.5%
−51.0%
−22.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −51.0% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−3277 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -3269.4% · Net -3277.2%
-1000%-2000%-3000%2014201620182020202220242025
ROE
FY2024 · ROE -45.2%
-200%-400%2014201620182020202220242025

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2023 · FCF -17.0
-20M2014201620182020202220242025

Total assetsUSD 6.5M
CashUSD 5.0M
Current ratio1.99×

Not available: we don't have the total debt figure for this period.

The 12-year record
12 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017201620152014
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B·−0.0−0.0−0.0−0.1−0.0−0.0·····
Income tax $B·0.00.0−0.0−0.0−0.00.00.00.00.0−0.00.0
Net income $B−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B··−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−4.86−6001.39−110.87−108.90−288.97−5.54−5.03−19.64−2.08−4.85−27.14−18.61
Dividend / sh $············
Payout %············
ROE %·−45.2−220.6−192.6−214.7−112.1−127.2−155.0−69.9−446.6··
Shares out B0.010.000.000.000.000.000.010.000.020.020.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 58 reconciliationsAUDITED

Reconciled in 12 of 19 fiscal years. 37 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2014

Share this section

Download image